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West Nile virus (WNV) is a mosquito-borne zoonotic arbovirus belonging to the genus 
Flavivirus in the family Flaviviridae. This flavivirus is found in temperate and tropical regions 
of the world. WNV has spread globally, with the first case in the Western Hemisphere being 
identified in New York City in 1999; over the next 5 years, the virus spread across the 
continental United States, north into Canada, and southward into the Caribbean Islands and 
Latin America. WNV is now considered to be an endemic pathogen in Africa, Asia, Australia, 
the Middle East, Europe and in the United States, which in 2012 has experienced one of its 
worst epidemics, when WNV was killing 286 people in Texas. 
Phylogenetic studies have identified 2 main lineages of WNV strains. In the early 2000-s 
strains from lineage1 were present in Africa, India, and Australia and were reponsible for 
outbreaks in Europe, in the Mediterranean Basin, and in North America, whereas lineage 2 
strains had been reported only in sub-Saharan Africa and Madagascar.The Hungarian equine 
WNV outbreak reported in 2008 was the first to be caused by a lineage 2 sub-Saharan strain in 
Europe. The pathogenicity of this lineage 2 strain resembled that of lineage 1 strains, and its 
sudden spread was unpredictable. 
The main mode of WNV transmission is via various species of mosquitoes which are the 
prime vector, with birds being the most commonly infected animal and serving as the prime 
reservoir host. Birds develop sufficient viral levels after being infected, to transmit the 
infection to other biting mosquitoes which in turn go on to infect other birds. In some species 
of birds, the infection is fatal. When the mosquitoes become less selective, -during late 
summer and early autumn, when migrating birds leave their previous living area-, begin 
feeding more readily on other animal types such as humans and horses which are considered 
incidental hosts. In mammals, the virus does not multiply as readily (i.e. does not develop 
high viremia during infection), and mosquitoes biting infected mammals are not believed to 
ingest sufficient virus to become infected, making mammals like humans and equines, so-
called dead-end hosts. In our climatic area (Middle Europe) equine outbreaks of the disease 
occur according to strict seasonality between August and October. 
Approximately 80% of WNV infections in humans are subclinical, and this is very similar to 
horses where most infections are asymptomatic. In humans West Nile fever (WNF), which 
occurs in 20 percent of cases, is a febrile syndrome that causes flu-like symptoms, like fever, 
headaches, fatigue and muscle pain. Whether this type of syndrome exist in horses is not 
clear, because we only identify cases with neurologic signs and might miss these non-typical 
transient conditions. In humans less than 1% of the cases is severe and result in neurological 
disease when the central nervous system is affected. Horses are particularly sensitive to WNV 
with approximately 10% infected animals presenting neurological disorders. 
In horses the disease might start with non-specific signs of general depression, loss of 
appetite, low-grade fever, colic-like symptoms, lameness, stiffness or poor performance. 
Weakness, ataxia, and paralysis, -sometimes assymetrical-, are typical features of nervous 
system involvement in WNV infections and these usually develop primarily in the 
hindquarters in previously described lineage 1 outbreaks. In many cases caused by lineage 2 
viruses, these signs are more prominent in the forelimbs at the onset of the disease. Limb 
paralysis can affect one or two limbs or all four, the latter usually progressing into 
recumbency and result in poor prognosis. Skin fasciculations and muscle tremors on the face, 
neck, pectoral and triceps area are common. Cranial nerve abnormalities, like facial paralysis, 
dysphagia or vestibular symptomes can be observed less frequently. In a lineage 2 outbreak 
we have described head posture abnormalities, hyperexcitability, but abnormal behaviour was 
less common than in lineage 1 north-american outbreaks. Factors other than the strain alone 
may account for the clinical manifestation of disease. Individual factors of receptivity also are 
thought to be of major importance for the evolution and clinical expression of WNV infection. 
Indeed, several authors have demonstrated that variations in certain loci of the host’s genome 
influenced susceptibility and clinical presentation. Furthermore, the presence of antibodies 
against other flaviviruses is thought to play a role in determining the clinical presentation in 
certain areas.  
Laboratory results are non-specific and can be completely negative. In severe cases we find 
pronounced increases in WBC counts with neutrophilia. In most cases cerebrospinal fluid 
sampling (CSF) is performed in the lumbosacral region. The CSF is abnormal in most cases 
showing mononuclear pleocytosis with lymphocytic predominance, but in some cases, only a 
high protein concentration can be found. Neutrophil predominance in CSF is also a sign of 
poor prognosis.  
Following peripheral inoculation, initial WNV replication is thought to occur in skin 
Langerhans dendritic cells. These cells migrate to and seed draining lymph nodes, resulting in 
a primary viremia and subsequent infection of peripheral tissues such as the spleen and 
kidney. By the end of the first week, WNV is largely cleared from the serum and peripheral 
organs and infection of the central nervous system (CNS) is observed in a subset of 
immunocompetent animals. The mechanisms by which WNV and other neurotropic 
flaviviruses cross the blood-brain barrier remain largely unknown, although tumor necrosis 
factor alpha (TNF-α)-mediated changes in endothelial cell permeability may facilitate CNS 
entry. It is likely that WNV infects the CNS at least in part via hematogenous spread, as an 
increased viral burden in serum correlates with earlier viral entry into the brain. 
The virus causes polioencephalomyelitis in horses and men. There is usually relatively mild 
gliosis and perivascular cuffing, lymphocytic and neutrophilic infiltration, neuronophagia, 
necrosis of neuros and a few scattered perivascular haemorrhages in the cerebrum, with the 
most severe disease located in the thalamus and hindbrain. The most severe sites of the WN 
neuroinvasive disease lesions can be focally distributed, but usually there is generalized 
inflammation. The grey matter of the spinal cord can be severely affected as well. 
The differential diagnosis in Europe mainly includes the neurological form of 
rhinopneumonia of Equine Herpes Virus 1, Borna disease, and rabies. We have to exclude 
CNS trauma, plant and other toxicoses, bacterial meningitis, Wobbler syndrome and some 
degenerative disorders. In the Western Hemisphere arboviral encephalitis (e.g., Venezuelan, 
Eastern, and Western encephalomyelitis) and equine protozoal myeloencephalitis (Sarcosystis 
neurona or Neospora hughesi) have to be included in the differentials.  
The antemortem diagnosis of acute WNV infection is based on the detection of specific IgM 
antibodies in serum, CSF or both by an ELISA test or an increase in IgG titers between acute-
phase and convalescent sera. Virus-neutralizing antibody responses persist for longer than 
WNV-specific IgM levels in serum. The duration of IgM appears to be short-lived in horses 
and this is the reason why it is useful for identifying and differentiating recent infections from 
previously exposed animals. It is well known that there is an extensive cross-reactive antibody 
response to members of the Flavivirus genus, thus molecular tests should be performed to 
confirm the clinical diagnosis and identify the causative virus. Horses infected with either 
WNV lineage 1 or lineage 2 elicit a similar antibody profile in serum samples and there are 
not any notable differences in the antibody profile.  
Most data show that tests to detect WNV RNA in serum or plasma may give false-negative 
results due to the short duration of viraemia. Consistent with the fact that the kidney is a well-
established site of active WNV replication in animals, urine samples may be more appropriate 
when looking for the presence of WNV, because of longer shedding and higher viral load. 
Whole WNV genome reconstruction is also easily achieved from the urine sample in humans. 
Reliability of testing urine for viral RNA in horses has not been established yet. 
What is going on in European countries? In Hungary WNV became endemic causing equine 
and human disease each year. According to previous isolations we suppose that both lineage 1 
and lineage 2 strains are circulating in Hungary but only lineage 2 strains were isolated from 
neuroinvasive animal cases in recent years. A human outbreak of WNV infections occurred in 
2010 in central Macedonia, northern Greece. WNV lineage 2 sequences were obtained from 
mosquitoes in sites where encephalitis cases occurred a few days before the trapping. The 
Greek strain showed the highest homology to Hungarian and South African strains, differing 
from the Russian WNV lineage 2 strain, which suggests that at least two lineage 2 strains 
have been introduced and established in Europe, causing severe disease to humans and horses. 
Notably, cases of WNV infection in Greece in 2011 occurred in areas that had not been 
affected in 2010. WNV infections have been reported in both humans and horses since the 
summer of 2008 in north-eastern Italy as well. Until 2011 only WNV lineage 1 infections 
have been described in the country. In 2011 Bagnarelly et al. described a human case of WNF 
which was confirmed to be caused by a lineage 2 virus. It also showed 99% identity to the 
complete genome of isolate goshawk-Hungary/04 and to the more recent Nea Santa-Greece-
2010. Between July and September 2012, Barzon et al. described 13 confirmed human cases 
of WNV infection diagnosed in north-eastern Italy. Cases occurred one month earlier than 
previously reported, and this could be attributable to the ongoing very hot summer season, 
probably responsible for the very high mosquito density, that has been observed in the 
affected areas. The outbreak was caused by the lineage 1 Livenza strain which is classified 
within the Mediterranean cluster, but has several novel amino acid substitutions in non-
structural proteins that are not present in other European and non-European strains, that could 
be relevant for virus transmissibility and neuroinvasive potential.  
Although much remains to be learned about the specific mechanisms that define immunity 
against WNV, both humoral and cellular responses likely are essential for protection. Specific 
neutralizing antibodies are generated at late times after primary WNV infection, and the 
development of high-titer neutralizing antibodies after vaccination correlates with protection 
against challenge. Nevertheless, it remains unknown how the epitope specificity of the 
antibody repertoire contributes to protective memory responses. T-cell-mediated immunity is 
also likely necessary to resist a second WNV challenge. Immunization with different WNV 
vaccine preparations can induce memory T cells, although the relative contribution of 
humoral versus cellular memory to vaccine efficacy remains largely undefined. The 
emergence of lineage 2 strains of WNV in Europe as a cause of clinical disease and mortality 
in horses raised the question whether the existing WNV vaccines, all based on lineage 1 
strains, protect against circulating lineage 2 strains of WNV. The lineage 1 vaccines tested so 
far against lineage 2 starins protected against the disease, and so would provide veterinarians 
with an effective tool to control infections caused by lineage 1 and 2 strains of WNV. 
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